JP2012529423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529423A5 JP2012529423A5 JP2011552249A JP2011552249A JP2012529423A5 JP 2012529423 A5 JP2012529423 A5 JP 2012529423A5 JP 2011552249 A JP2011552249 A JP 2011552249A JP 2011552249 A JP2011552249 A JP 2011552249A JP 2012529423 A5 JP2012529423 A5 JP 2012529423A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- peptide
- modified
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 159
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 110
- 229940024606 amino acid Drugs 0.000 claims description 61
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 57
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 56
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 54
- 229930182817 methionine Natural products 0.000 claims description 54
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 34
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 34
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 34
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 34
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 20
- 239000004474 valine Substances 0.000 claims description 20
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 17
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 17
- 229960000310 isoleucine Drugs 0.000 claims description 17
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 17
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 108091008605 VEGF receptors Proteins 0.000 claims 8
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 8
- 238000007792 addition Methods 0.000 claims 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 230000001939 inductive effect Effects 0.000 claims 8
- 238000003780 insertion Methods 0.000 claims 8
- 230000037431 insertion Effects 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 206010029113 Neovascularisation Diseases 0.000 claims 6
- 210000003161 choroid Anatomy 0.000 claims 6
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000038015 macular disease Diseases 0.000 claims 4
- 108091005601 modified peptides Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000033379 Chorioretinopathy Diseases 0.000 claims 2
- 208000024080 Myopic macular degeneration Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000008798 osteoma Diseases 0.000 claims 2
- 239000000790 retinal pigment Substances 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical class CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011552249A JP5688587B2 (ja) | 2009-06-11 | 2010-06-10 | 脈絡膜新血管新生に対するワクチン療法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009140363 | 2009-06-11 | ||
| JP2009140363 | 2009-06-11 | ||
| PCT/JP2010/003871 WO2010143435A1 (en) | 2009-06-11 | 2010-06-10 | Vaccine therapy for choroidal neovascularization |
| JP2011552249A JP5688587B2 (ja) | 2009-06-11 | 2010-06-10 | 脈絡膜新血管新生に対するワクチン療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529423A JP2012529423A (ja) | 2012-11-22 |
| JP2012529423A5 true JP2012529423A5 (enExample) | 2013-07-25 |
| JP5688587B2 JP5688587B2 (ja) | 2015-03-25 |
Family
ID=43308696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552249A Expired - Fee Related JP5688587B2 (ja) | 2009-06-11 | 2010-06-10 | 脈絡膜新血管新生に対するワクチン療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8975229B2 (enExample) |
| EP (1) | EP2440226A4 (enExample) |
| JP (1) | JP5688587B2 (enExample) |
| KR (1) | KR20120038419A (enExample) |
| CN (1) | CN102802654A (enExample) |
| AU (1) | AU2010259797B2 (enExample) |
| BR (1) | BRPI1013025A2 (enExample) |
| CA (1) | CA2764562A1 (enExample) |
| IL (1) | IL216402A0 (enExample) |
| MX (1) | MX2011012659A (enExample) |
| RU (1) | RU2555345C2 (enExample) |
| SG (2) | SG176737A1 (enExample) |
| TW (1) | TW201109029A (enExample) |
| WO (1) | WO2010143435A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289532A1 (en) | 2005-02-28 | 2011-03-02 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| WO2008099908A1 (ja) * | 2007-02-16 | 2008-08-21 | Oncotherapy Science, Inc. | 脈絡膜新生血管のワクチン療法 |
| FR2990352A1 (fr) | 2012-05-10 | 2013-11-15 | Univ Paris 13 | Composition immunogene comprenant un peptide derive du vegf et ses utilisations |
| JP7168228B2 (ja) * | 2017-05-19 | 2022-11-09 | 慶應義塾 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| CN1173991C (zh) | 1992-11-13 | 2004-11-03 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k-1 |
| WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Ｖｅｇｆ結合性ポリペプチド |
| DE69838334T2 (de) | 1997-06-18 | 2008-06-12 | Merck & Co., Inc. (A New Jersey Corp.) | Kdr, ein menschlicher tyrosin kinase rezeptor |
| WO1999040118A1 (en) | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| WO1999059636A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
| AU6600400A (en) | 1999-08-13 | 2001-03-13 | Crucell Holland B.V. | Methods and means for inhibiting angiogenesis |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| AU2002362461A1 (en) | 2001-10-01 | 2003-04-14 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| JP2006511475A (ja) | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 脈絡膜新生血管症の抑制方法 |
| ES2687645T3 (es) | 2003-10-27 | 2018-10-26 | Merck Sharp & Dohme Corp. | Método de diseño de ARNip para el silenciamiento de genes |
| JP2006215988A (ja) * | 2005-02-07 | 2006-08-17 | Ntt Docomo Kansai Inc | 認証システム、携帯端末装置及び認証方法 |
| EP2289532A1 (en) * | 2005-02-28 | 2011-03-02 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| US20060234941A1 (en) * | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| JP2006315988A (ja) | 2005-05-11 | 2006-11-24 | Mototake Shimizu | ケモカイン産生誘導効果を有する血管新生阻害物質 |
| WO2008099908A1 (ja) | 2007-02-16 | 2008-08-21 | Oncotherapy Science, Inc. | 脈絡膜新生血管のワクチン療法 |
| US8354223B2 (en) | 2007-06-14 | 2013-01-15 | Oncotherapy Science, Inc. | Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3 |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
-
2010
- 2010-06-08 TW TW099118513A patent/TW201109029A/zh unknown
- 2010-06-10 RU RU2012100241/15A patent/RU2555345C2/ru not_active IP Right Cessation
- 2010-06-10 MX MX2011012659A patent/MX2011012659A/es active IP Right Grant
- 2010-06-10 AU AU2010259797A patent/AU2010259797B2/en not_active Expired - Fee Related
- 2010-06-10 EP EP10785967.0A patent/EP2440226A4/en not_active Withdrawn
- 2010-06-10 SG SG2011090933A patent/SG176737A1/en unknown
- 2010-06-10 BR BRPI1013025A patent/BRPI1013025A2/pt not_active IP Right Cessation
- 2010-06-10 SG SG10201403109VA patent/SG10201403109VA/en unknown
- 2010-06-10 CA CA2764562A patent/CA2764562A1/en not_active Abandoned
- 2010-06-10 CN CN2010800356548A patent/CN102802654A/zh active Pending
- 2010-06-10 JP JP2011552249A patent/JP5688587B2/ja not_active Expired - Fee Related
- 2010-06-10 US US13/377,110 patent/US8975229B2/en not_active Expired - Fee Related
- 2010-06-10 KR KR1020117031702A patent/KR20120038419A/ko not_active Withdrawn
- 2010-06-10 WO PCT/JP2010/003871 patent/WO2010143435A1/en not_active Ceased
-
2011
- 2011-11-17 IL IL216402A patent/IL216402A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500001A5 (enExample) | ||
| TWI482626B (zh) | 胃腸道病症的治療 | |
| JP7705160B2 (ja) | 生物活性複合体の調製 | |
| JP6585720B2 (ja) | 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物 | |
| CN105939723B (zh) | 前列腺癌治疗用组合物 | |
| JP2014521684A5 (enExample) | ||
| CN108064163B (zh) | 血管生成性疾病的免疫疗法 | |
| JP2002514658A (ja) | β−アミロイド前駆体タンパク質およびユビキチンＢのフレームシフト変異体ならびにその使用 | |
| JP2010516290A5 (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| RS61230B1 (sr) | Lečenje neuroloških bolesti | |
| JP2014506450A5 (enExample) | ||
| JP2016510728A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| JP2019535651A5 (enExample) | ||
| CN110945010A (zh) | 肽组合物和相关方法 | |
| JP2016536369A5 (enExample) | ||
| JP2012529423A5 (enExample) | ||
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| JP2018533912A5 (enExample) | ||
| BR112019026336A2 (pt) | forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico | |
| RU2013103487A (ru) | Вакцинотерапия неоваскуляризации сосудистой оболочки глаза | |
| JP2008531463A5 (enExample) | ||
| JP2019519466A5 (enExample) |